Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 49.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,887 shares of the biopharmaceutical company’s stock after acquiring an additional 3,274 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Bristol-Myers Squibb were worth $512,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. GAM Holding AG lifted its stake in Bristol-Myers Squibb by 0.7% during the 3rd quarter. GAM Holding AG now owns 242,009 shares of the biopharmaceutical company’s stock worth $12,522,000 after acquiring an additional 1,733 shares in the last quarter. Tempus Wealth Planning LLC lifted its stake in Bristol-Myers Squibb by 1.5% during the 3rd quarter. Tempus Wealth Planning LLC now owns 15,648 shares of the biopharmaceutical company’s stock worth $810,000 after acquiring an additional 235 shares in the last quarter. Westhampton Capital LLC lifted its stake in Bristol-Myers Squibb by 75.4% during the 3rd quarter. Westhampton Capital LLC now owns 27,217 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 11,700 shares in the last quarter. Symphony Financial Ltd. Co. lifted its stake in Bristol-Myers Squibb by 36.4% during the 3rd quarter. Symphony Financial Ltd. Co. now owns 17,802 shares of the biopharmaceutical company’s stock worth $930,000 after acquiring an additional 4,751 shares in the last quarter. Finally, Eastern Bank lifted its stake in Bristol-Myers Squibb by 715.3% during the 3rd quarter. Eastern Bank now owns 45,290 shares of the biopharmaceutical company’s stock worth $2,343,000 after acquiring an additional 39,735 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on BMY shares. UBS Group upped their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Barclays upped their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft cut their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Finally, TD Cowen upped their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $53.20.

Bristol-Myers Squibb Trading Up 0.6 %

BMY opened at $53.06 on Thursday. The firm has a market cap of $107.56 billion, a price-to-earnings ratio of -17.12, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $56.77. The business’s 50 day moving average is $50.63 and its two-hundred day moving average is $46.39. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the previous year, the company posted $1.75 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. On average, research analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.